Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

Shokeen M, Anderson CJ.

Acc Chem Res. 2009 Jul 21;42(7):832-41. doi: 10.1021/ar800255q.

2.

Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Anderson CJ, Ferdani R.

Cancer Biother Radiopharm. 2009 Aug;24(4):379-93. doi: 10.1089/cbr.2009.0674.

3.

Copper chelation chemistry and its role in copper radiopharmaceuticals.

Wadas TJ, Wong EH, Weisman GR, Anderson CJ.

Curr Pharm Des. 2007;13(1):3-16. Review.

PMID:
17266585
4.

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.

Cai Z, Anderson CJ.

J Labelled Comp Radiopharm. 2014 Apr;57(4):224-30. doi: 10.1002/jlcr.3165. Epub 2013 Dec 18. Review.

5.

The development of copper radiopharmaceuticals for imaging and therapy.

Shokeen M, Wadas TJ.

Med Chem. 2011 Sep;7(5):413-29. Review.

PMID:
21711219
6.

Recent advances in copper radiopharmaceuticals.

Hao G, Singh AN, Oz OK, Sun X.

Curr Radiopharm. 2011 Apr;4(2):109-21. Review.

PMID:
22191650
7.

Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.

Miao Z, Ren G, Liu H, Jiang L, Cheng Z.

Bioconjug Chem. 2010 May 19;21(5):947-54. doi: 10.1021/bc900515p.

PMID:
20402512
8.

Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.

Zeng D, Guo Y, White AG, Cai Z, Modi J, Ferdani R, Anderson CJ.

Mol Pharm. 2014 Nov 3;11(11):3980-7. doi: 10.1021/mp500004m. Epub 2014 Apr 25.

9.

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8674-82.

10.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
11.

Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.

Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, Paudyal B, Higuchi T, Oriuchi N, Endo K.

Ann Nucl Med. 2009 Aug;23(6):559-67. doi: 10.1007/s12149-009-0274-0. Epub 2009 Jun 6.

PMID:
19504168
12.

Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold.

Kumar A, Hao G, Liu L, Ramezani S, Hsieh JT, Öz OK, Sun X.

Bioconjug Chem. 2015 Apr 15;26(4):782-9. doi: 10.1021/acs.bioconjchem.5b00102. Epub 2015 Mar 19.

PMID:
25760776
13.

Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging.

Anderson CJ, Wadas TJ, Wong EH, Weisman GR.

Q J Nucl Med Mol Imaging. 2008 Jun;52(2):185-92. Epub 2007 Nov 28. Review.

15.

Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.

Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, Li P, Gambhir SS, Cochran JR, Cheng Z.

J Nucl Med. 2010 Feb;51(2):251-8. doi: 10.2967/jnumed.109.069831.

16.

Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.

Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, Anderson CJ.

J Med Chem. 2004 Mar 11;47(6):1465-74.

PMID:
14998334
17.

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.

PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.

18.

Somatostatin receptor PET imaging with Gallium-68 labeled peptides.

Win Z, Al-Nahhas A, Rubello D, Gross MD.

Q J Nucl Med Mol Imaging. 2007 Sep;51(3):244-50. Epub 2007 Apr 30. Review.

PMID:
17464267
19.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

20.

Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.

Persson M, Hosseini M, Madsen J, Jørgensen TJ, Jensen KJ, Kjaer A, Ploug M.

Theranostics. 2013 Aug 3;3(9):618-32. doi: 10.7150/thno.6810. eCollection 2013.

Supplemental Content

Support Center